Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine

被引：24

作者：

Mehta, Darshan ^{[1
]}

Uber, Ryley ^{[2
,5
]}

Ingle, Taylor ^{[1
]}

Li, Catherine ^{[3
]}

Liu, Zhichao ^{[1
]}

Thakkar, Shraddha ^{[1
]}

Ning, Baitang ^{[1
]}

Wu, Leihong ^{[1
]}

Yang, Junshuang ^{[1
]}

Harris, Steve ^{[1
]}

Zhou, Guangxu ^{[1
]}

Xu, Joshua ^{[1
]}

Tong, Weida ^{[1
]}

Lesko, Lawrence ^{[4
]}

Fang, Hong ^{[1
]}

机构：

[1] US FDA, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA

[2] Univ Pittsburg, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA

[3] US FDA, Off Translat Sci, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA

[4] Univ Florida, Coll Pharm, Orlando, FL 32827 USA

[5] US FDA, Oak Ridge Inst Sci & Educ, Res Participat Program, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA

来源：

DRUG DISCOVERY TODAY | 2020年 / 25卷 / 05期

关键词：

IMPLEMENTATION CONSORTIUM; BIOMARKERS; THERAPY;

D O I：

10.1016/j.drudis.2020.01.023

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Pharmacogenomics (PGx), studying the relationship between drug response and genetic makeup of an individual, is accelerating advances in precision medicine. The FDA includes PGx information in the labeling of approved drugs to better inform on their safety and effectiveness. We herein present a summary of PGx information found in 261 prescription drug labeling documents by querying the publicly available FDALabel database. A total of 362 drug-biomarker pairs (DBPs) were identified. We profiled DBPs using frequency of the biomarkers and their therapeutic classes. Four categories of applications (indication, safety, dosing and information) were discussed according to information in labeling. This analysis facilitates better understanding, utilization and translation of PGx information in drug labeling among researchers, healthcare professionals and the public.

引用

页码：813 / 820

页数：8

共 50 条

[41] Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs
Vivot, Alexandre
Boutron, Isabelle
Ravaud, Philippe
Porcher, Raphael
GENETICS IN MEDICINE, 2015, 17 (09) : 733 - 738
[42] FDA-approved drug promotes remyelination
Sarah Lempriere
Nature Reviews Neurology, 2022, 18 : 637 - 637
[43] FDA-approved drug promotes remyelination
不详
NATURE REVIEWS NEUROLOGY, 2022, 18 (11) : 637 - 637
[44] Pharmacogenetic Labeling of FDA-Approved Drugs A Regulatory Retrospective
Drozda, Katarzyna
Pacanowski, Michael A.
Grimstein, Christian
Zineh, Issam
JACC-BASIC TO TRANSLATIONAL SCIENCE, 2018, 3 (04): : 545 - 549
[45] Genomic biomarkers in FDA-approved drug labels
Mummaneni, Padmaja
Amur, Shashi G.
Goodsaid, Federico
Rudman, Allen
Frueh, Felix W.
JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (09): : 1088 - 1088
[46] Understanding FDA-Approved Labeling and CDC Recommendations for Use of Vaccines
Meissner, H. Cody
Farizo, Karen
Pratt, Douglas
Pickering, Larry K.
Cohn, Amanda C.
PEDIATRICS, 2018, 142 (03)
[47] Towards precision medicine: Cataloging FDA-approved actionable mutations in The Cancer Genome Atlas.
Dan, Tu
Palmer, Joshua David
Mishra, Mark Vikas
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[48] Outdated Prescription Drug Labeling: How FDA-Approved Prescribing Information Lags Behind Real-World Clinical Practice
Michael B. Shea
Mark Stewart
Hugo Van Dyke
Linda Ostermann
Jeff Allen
Ellen Sigal
Therapeutic Innovation & Regulatory Science, 2018, 52 : 771 - 777
[49] Outdated Prescription Drug Labeling How FDA-Approved Prescribing Information Lags Behind Real-World Clinical Practice
Shea, Michael B.
Stewart, Mark
Van Dyke, Hugo
Ostermann, Linda
Allen, Jeff
Sigal, Ellen
THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2018, 52 (06) : 771 - 777
[50] Consistency of drug-drug and gene-drug interaction information in US FDA-approved drug labels
Conrado, Daniela J.
Rogers, Hobart L.
Zineh, Issam
Pacanowski, Michael A.
PHARMACOGENOMICS, 2013, 14 (02) : 215 - 223

← 1 2 3 4 5 →